These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17452420)
1. Combination silencer RNA (siRNA) targeting Bcl-2 antagonizes siRNA against thymidylate synthase in human tumor cell lines. Pandyra AA; Berg R; Vincent M; Koropatnick J J Pharmacol Exp Ther; 2007 Jul; 322(1):123-32. PubMed ID: 17452420 [TBL] [Abstract][Full Text] [Related]
2. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. Di Cresce C; Figueredo R; Ferguson PJ; Vincent MD; Koropatnick J J Pharmacol Exp Ther; 2011 Sep; 338(3):952-63. PubMed ID: 21673071 [TBL] [Abstract][Full Text] [Related]
3. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Berg RW; Ferguson PJ; Vincent MD; Koropatnick DJ Cancer Gene Ther; 2003 Apr; 10(4):278-86. PubMed ID: 12679800 [TBL] [Abstract][Full Text] [Related]
4. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Ferguson PJ; Collins O; Dean NM; DeMoor J; Li CS; Vincent MD; Koropatnick J Br J Pharmacol; 1999 Aug; 127(8):1777-86. PubMed ID: 10482907 [TBL] [Abstract][Full Text] [Related]
5. ODN 491, a novel antisense oligodeoxynucleotide that targets thymidylate synthase, exerts cell-specific effects in human tumor cell lines. Jason TL; Figueredo R; Ferguson PJ; Vincent MD; Berg RW; Koropatnick J DNA Cell Biol; 2008 May; 27(5):229-40. PubMed ID: 18358073 [TBL] [Abstract][Full Text] [Related]
6. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. Berg RW; Werner M; Ferguson PJ; Postenka C; Vincent M; Koropatnick DJ; Behrend E J Pharmacol Exp Ther; 2001 Aug; 298(2):477-84. PubMed ID: 11454908 [TBL] [Abstract][Full Text] [Related]
7. Antisense targeting of thymidylate synthase (TS) mRNA increases TS gene transcription and TS protein: effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs. Jason TL; Berg RW; Vincent MD; Koropatnick J Gene Expr; 2007; 13(4-5):227-39. PubMed ID: 17605297 [TBL] [Abstract][Full Text] [Related]
8. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: shoot the messenger. Berg RW; Ferguso PJ; DeMoor JM; Vincen MD; Koropatnick J Curr Drug Targets; 2002 Aug; 3(4):297-309. PubMed ID: 12102601 [TBL] [Abstract][Full Text] [Related]
9. [Effects of RNA interference and nolatrexed on thymidylate synthase expression and cell proliferation of human colorectal carcinoma LOVO cells]. Tian SB; Jing CQ; Li LP Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Nov; 15(11):1187-91. PubMed ID: 23172536 [TBL] [Abstract][Full Text] [Related]
10. Stable inhibition of human thymidylate synthase expression following retroviral introduction of an siRNA gene. Yang Z; Cloud A; Hughes D; Johnson LF Cancer Gene Ther; 2006 Jan; 13(1):107-14. PubMed ID: 16052228 [TBL] [Abstract][Full Text] [Related]
11. Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents. Yawata A; Kim SR; Miyajima A; Kubo T; Ishida S; Saito Y; Nakajima Y; Katori N; Matsumoto Y; Fukuoka M; Ohno Y; Ozawa S; Sawada J Cancer Chemother Pharmacol; 2005 Nov; 56(5):465-72. PubMed ID: 15918040 [TBL] [Abstract][Full Text] [Related]
12. bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Fisher TC; Milner AE; Gregory CD; Jackman AL; Aherne GW; Hartley JA; Dive C; Hickman JA Cancer Res; 1993 Jul; 53(14):3321-6. PubMed ID: 8324744 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of thymidylate synthase activity by antisense oligodeoxynucleotide and possible role in thymineless treatment. Lin SB; Ts'o PO; Sun SK; Choo KB; Yang FY; Lim YP; Tsai HL; Au LC Mol Pharmacol; 2001 Sep; 60(3):474-9. PubMed ID: 11502877 [TBL] [Abstract][Full Text] [Related]
14. Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Beh CW; Seow WY; Wang Y; Zhang Y; Ong ZY; Ee PL; Yang YY Biomacromolecules; 2009 Jan; 10(1):41-8. PubMed ID: 19072631 [TBL] [Abstract][Full Text] [Related]
15. Differentiation-inducing factor-1 enhances 5-fluorouracil action on oral cancer cells inhibiting E2F1 and thymidylate synthase mRNAs accumulation. Sprio AE; Di Scipio F; Ceppi P; Salamone P; Di Carlo F; Scagliotti GV; Papotti M; Ceccarelli A; Berta GN Cancer Chemother Pharmacol; 2012 Apr; 69(4):983-9. PubMed ID: 22139443 [TBL] [Abstract][Full Text] [Related]
16. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. Ju J; Kane SE; Lenz HJ; Danenberg KD; Chu E; Danenberg PV Clin Cancer Res; 1998 Sep; 4(9):2229-36. PubMed ID: 9748143 [TBL] [Abstract][Full Text] [Related]
17. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056 [TBL] [Abstract][Full Text] [Related]
18. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082 [TBL] [Abstract][Full Text] [Related]
19. Targeting of cell survival genes using small interfering RNAs (siRNAs) enhances radiosensitivity of Grade II chondrosarcoma cells. Kim DW; Seo SW; Cho SK; Chang SS; Lee HW; Lee SE; Block JA; Hei TK; Lee FY J Orthop Res; 2007 Jun; 25(6):820-8. PubMed ID: 17343283 [TBL] [Abstract][Full Text] [Related]
20. Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1. Yde CW; Issinger OG Int J Oncol; 2006 Dec; 29(6):1397-404. PubMed ID: 17088977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]